Drug intelligence / Profile preview

ve-2843

Development stage: Preclinical
Lead developer: Verseon
Modality: Small Molecules

Overview

VE-2843 is a small molecule drug developed as a matriptase inhibitor. It is being investigated for the treatment of solid tumors, with its primary mechanism of action being inhibition of the ST14 transmembrane serine protease matriptase. The drug was initially developed by Verseon Corp., and its highest global R&D status is currently Discovery[1][2].

Targets

ST14 (Matriptase)

Beyond the preview

Go deeper on ve-2843.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ve-2843.

Explore the full profile